Treventis
Toronto
About Treventis
TREVENTIS Corporation is dedicated to treating and preventing protein misfolding diseases. We utilize a proprietary, patent-pending discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets. Our lead program focuses on anti-misfolding small molecules in tauopathy (3R, 4R, familial mutations and mixed) with relevance to Alzheimer’s disease. We have further CCM-driven efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $7.9M
- Funding stage: Seed
- Last round: Grant (Oct 2022)
- Website: treventis.com
- Phone: 6472281276
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/treventis-25351 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.